The FY17 Defense Appropriations Act provides $5 million (M) to the Department of Defense Lupus Research Program (LRP) to support innovative and impactful research that addresses fundamental issues in lupus. As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency (DHA) J9, Research and Development Directorate manages the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation. The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP).
The LRP is providing the information in this pre-announcement to allow investigators time to plan and develop applications. FY17 LRP Program Announcements and General Application Instructions for the following award mechanisms are anticipated to be posted on the Grants.gov website in October 2017. Pre-application and application deadlines will be available when the Program Announcements are released. This pre-announcement should not be construed as an obligation by the government.
Applications submitted to the FY17 LRP must address at least one of the three Focus Areas listed below:
• Understand lupus disease heterogeneity including, but not limited to, progressive stages of lupus disease over time, strategies and technologies to subtype patients, lupus disease mechanisms, biopsychosocial studies, personalized medicine, variation in treatment and its effects on patient outcomes, socioeconomic studies, environmental studies, and epidemiological studies.
• Understand how the underlying genetic components of lupus disease relate to clinical disease characteristics using functional genomic studies.
• Determine the pathobiology of lupus in target human tissues including, but not limited to, imaging studies, genetics of lupus disease in particular tissues, and metabolomics.
- Investigators at all academic levels
· Supports highly innovative, untested, potentially groundbreaking concepts in lupus research
· Emphasis is on innovation
· Clinical trials are not allowed
- Preliminary data is discouraged
· Maximum funding of $150,000 for total costs
- Maximum period of performance is 1 year
- Investigators at or above Assistant Professor (or equivalent)
· Supports innovative, high-risk/high-reward research
· Emphasis is on impact
· Clinical trials are not allowed
- Preliminary data is encouraged but not required
· Maximum funding of $525,000 for total costs
- Maximum period of performance is 3 years
A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline. All applications must conform to the final Program Announcements and General Application Instructions that will be available for electronic downloading from the Grants.gov website. The application package containing the required forms for each award mechanism will also be found on Grants.gov. A listing of all CDMRP funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420.
Applications must be submitted through the federal government’s single-entry portal, Grants.gov. Submission deadlines are not available until the Program Announcements are released. For email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org. For more information about the LRP or other CDMRP-administered programs, please visit the CDMRP website (http://cdmrp.army.mil).
Point of Contact:
CDMRP Public Affairs